Pretreatment Inflammatory Markers Predict Outcomes and Prognosis in Colorectal Cancer Patients With Synchronous Liver Metastasis.

INTRODUCTION

Pretreatment inflammatory markers were applied to predict the prognosis of colorectal cancer. However, the role of these markers in predicting survival in patients with synchronous colorectal liver metastasis (CLM) is rarely reported. Notably, lymphocyte-to-monocyte ratio (LMR) was mainly reported in hematologic malignancies and is worth to be further explored to predict the survival of synchronous CLM.

METHODS

Totally, 196 patients who were diagnosed with synchronous CLM were enrolled. Their clinical and laboratory data before treatment were collected, retrospectively. Univariate and multivariate analyses were performed to analyze the inflammatory biomarkers.

RESULTS

LMR ( = .002) and lactate dehydrogenase (LDH) ( = .017) were significantly related to the progression-free survival (PFS). More factors such as neutrophil-to-lymphocyte ratio (NLR) ( = .011), carbohydrate antigen 19-9 (CA19-9) ( = .001), number of metastatic foci ( = .006), and adjuvant chemotherapy ( = .027) were correlated with overall survival (OS). In multivariate analysis, LMR remained statistically associated with PFS ( = .003). Regarding OS, LMR ( = .016) and LDH ( = .013) were significantly independent predictive factors.

CONCLUSIONS

The higher LMR and lower LDH were strongly correlated with better survival in synchronous CLM patients. In addition, the result also indicated that enhanced LMR was related to better PFS. The LMR and LDH can be used to predict prognosis of the synchronous CLM.